1. Volume 146, Issue 2, Pages 420-429 (February 2014)
Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS in Treatment-Naive Patients With HCV Genotype 1 Infection 
Gregory T. Everson, Karen D. Sims, Maribel Rodriguez-Torres, Christophe Hézode, Eric Lawitz, Marc Bourlière, Veronique Loustaud- Ratti, Vinod Rustgi, Howard Schwartz, Harvey Tatum, Patrick Marcellin, Stanislas Pol, Paul J. Thuluvath, Timothy Eley, Xiaodong Wang, Shu-Pang Huang, Fiona McPhee, Megan Wind-Rotolo, Ellen Chung, Claudio Pasquinelli, Dennis M. Grasela, David F. Gardiner 
Gastroenterology 
Volume 146, Issue 2, Pages (February 2014)
DOI: /j.gastro
Copyright © 2014 AGA Institute Terms and Conditions

2. Figure 1
(A-D) HCV-RNA levels over time for individual patients in groups 1-4. Patients were treated with daclatasvir (60 mg, orally, once daily), asunaprevir (200 mg, orally, twice daily), plus (A) BMS mg twice daily for 24 weeks, (B) BMS mg twice daily for 12 weeks, (C) BMS mg twice daily for 24 weeks, (D) or BMS mg twice daily for 12 weeks. N equals 16 each for groups 1 through 3, and 18 for group 4. PT, post-treatment.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2014 AGA Institute Terms and Conditions